Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicole M Hermance

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Molecular Cancer Therapeutics|July 29, 2022
Suppression of Chromosome Instability Limits Acquired Drug ResistanceElizabeth A Crowley, Nicole M Hermance, Conor P Herlihy, et al.
Journal of Cell Science|August 3, 2021
Suv420 enrichment at the centromere limits Aurora B localization and functionConor P Herlihy, Sabine Hahn, Nicole M Hermance, et al.
Oncotarget|March 23, 2019
Aurora A inhibition limits centrosome clustering and promotes mitotic catastrophe in cells with supernumerary centrosomesBernat Navarro-Serer, Eva P Childers, Nicole M Hermance, et al.
Life Science Alliance|September 13, 2023
RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trappingLuis Gregory Zamalloa, Margaret M Pruitt, Nicole M Hermance, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
RB loss sensitizes cells to replication-associated DNA damage by PARP inhibitionL Gregory Zamalloa, Margaret M Pruitt, Nicole M Hermance, et al.
Haematologica|December 31, 2016
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T Fathi, Seth A Wander, Traci M Blonquist, et al.
The Lancet. Haematology|December 16, 2019
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trialAndrew M Brunner, Traci M Blonquist, Daniel J DeAngelo, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Molecular Cancer Therapeutics|July 29, 2022
Suppression of Chromosome Instability Limits Acquired Drug ResistanceElizabeth A Crowley, Nicole M Hermance, Conor P Herlihy, et al.
Journal of Cell Science|August 3, 2021
Suv420 enrichment at the centromere limits Aurora B localization and functionConor P Herlihy, Sabine Hahn, Nicole M Hermance, et al.
Oncotarget|March 23, 2019
Aurora A inhibition limits centrosome clustering and promotes mitotic catastrophe in cells with supernumerary centrosomesBernat Navarro-Serer, Eva P Childers, Nicole M Hermance, et al.
Life Science Alliance|September 13, 2023
RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trappingLuis Gregory Zamalloa, Margaret M Pruitt, Nicole M Hermance, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
RB loss sensitizes cells to replication-associated DNA damage by PARP inhibitionL Gregory Zamalloa, Margaret M Pruitt, Nicole M Hermance, et al.
Haematologica|December 31, 2016
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T Fathi, Seth A Wander, Traci M Blonquist, et al.
The Lancet. Haematology|December 16, 2019
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trialAndrew M Brunner, Traci M Blonquist, Daniel J DeAngelo, et al.
Pageof 1